TY - JOUR
T1 - S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival
AU - DeRycke, Melissa S.
AU - Andersen, John D.
AU - Harrington, Katherine M.
AU - Pambuccian, Stefan E.
AU - Kalloger, Steve E.
AU - Boylan, Kristin L.M.
AU - Argenta, Peter A.
AU - Skubitz, Amy P.N.
PY - 2009/12
Y1 - 2009/12
N2 - We sought to investigate the expression levels of S100A1 in ovarian cancer cell lines and tissues to correlate S100A1 with subtype, stage, grade, and relapse-free survival. S100A1 messenger RNA and protein were up-regulated in ovarian cancer cell lines and tumors compared with normal ovarian cell lines and tissues by gene microarray analysis, reverse transcriptase-polymerase chain reaction, quantitative reverse transcriptase-polymerase chain reaction, and Western immunoblotting. In the study, 63.7% of serous, 21.2% of clear cell, 11.2% of endometrioid, and 3% of mucinous ovarian (1/31) cancers were S100A1+ by immunohistochemical staining of tissue microarrays (n = 500). S100A1 expression increased with increasing Silverberg grade but not stage in serous tumors. Endometrial tissue microarrays (n = 127) were 9.4% S100A1+; no correlation with stage or grade and S100A1 was found. In the endometrioid subtype of ovarian and endometrial cancers, relapse-free survival was decreased for patients with S100A1+ tumors. These data suggest that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer.
AB - We sought to investigate the expression levels of S100A1 in ovarian cancer cell lines and tissues to correlate S100A1 with subtype, stage, grade, and relapse-free survival. S100A1 messenger RNA and protein were up-regulated in ovarian cancer cell lines and tumors compared with normal ovarian cell lines and tissues by gene microarray analysis, reverse transcriptase-polymerase chain reaction, quantitative reverse transcriptase-polymerase chain reaction, and Western immunoblotting. In the study, 63.7% of serous, 21.2% of clear cell, 11.2% of endometrioid, and 3% of mucinous ovarian (1/31) cancers were S100A1+ by immunohistochemical staining of tissue microarrays (n = 500). S100A1 expression increased with increasing Silverberg grade but not stage in serous tumors. Endometrial tissue microarrays (n = 127) were 9.4% S100A1+; no correlation with stage or grade and S100A1 was found. In the endometrioid subtype of ovarian and endometrial cancers, relapse-free survival was decreased for patients with S100A1+ tumors. These data suggest that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer.
KW - Endometrioid subtype
KW - Gene expression
KW - Ovarian cancer
KW - S100A1
KW - Tissue microarray
UR - http://www.scopus.com/inward/record.url?scp=72949122346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72949122346&partnerID=8YFLogxK
U2 - 10.1309/AJCPTK87EMMIKPFS
DO - 10.1309/AJCPTK87EMMIKPFS
M3 - Article
C2 - 19926575
AN - SCOPUS:72949122346
SN - 0002-9173
VL - 132
SP - 846
EP - 856
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 6
ER -
